rs121918623

Variant summary

Our verdict is Pathogenic. The variant received 19 ACMG points: 19P and 0B. PM1PM2PM5PP2PP3_StrongPP5_Very_Strong

The NM_001165963.4(SCN1A):​c.2624C>T​(p.Thr875Met) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.00000137 in 1,460,730 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. 14/22 in silico tools predict a damaging outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. T875R) has been classified as Uncertain significance.

Frequency

Genomes: not found (cov: 32)
Exomes 𝑓: 0.0000014 ( 0 hom. )

Consequence

SCN1A
NM_001165963.4 missense

Scores

17
1
1

Clinical Significance

Pathogenic/Likely pathogenic criteria provided, multiple submitters, no conflicts P:9O:1

Conservation

PhyloP100: 10.0

Publications

29 publications found
Variant links:
Genes affected
SCN1A (HGNC:10585): (sodium voltage-gated channel alpha subunit 1) Voltage-dependent sodium channels are heteromeric complexes that regulate sodium exchange between intracellular and extracellular spaces and are essential for the generation and propagation of action potentials in muscle cells and neurons. Each sodium channel is composed of a large pore-forming, glycosylated alpha subunit and two smaller beta subunits. This gene encodes a sodium channel alpha subunit, which has four homologous domains, each of which contains six transmembrane regions. Allelic variants of this gene are associated with generalized epilepsy with febrile seizures and epileptic encephalopathy. Alternative splicing results in multiple transcript variants. The RefSeq Project has decided to create four representative RefSeq records. Three of the transcript variants are supported by experimental evidence and the fourth contains alternate 5' untranslated exons, the exact combination of which have not been experimentally confirmed for the full-length transcript. [provided by RefSeq, Oct 2015]
SCN1A-AS1 (HGNC:54069): (SCN1A and SCN9A antisense RNA 1)

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Pathogenic. The variant received 19 ACMG points.

PM1
In a hotspot region, there are 8 aminoacids with missense pathogenic changes in the window of +-8 aminoacids around while only 0 benign, 11 uncertain in NM_001165963.4
PM2
Very rare variant in population databases, with high coverage;
PM5
Other missense variant is known to change same aminoacid residue: Variant chr2-166038098-G-T is described in ClinVar as Likely_pathogenic. ClinVar VariationId is 68594.Status of the report is criteria_provided_single_submitter, 1 stars.
PP2
Missense variant in the SCN1A gene, where missense mutations are typically associated with disease (based on misZ statistic). The gene has 848 curated pathogenic missense variants (we use a threshold of 10). The gene has 89 curated benign missense variants. Gene score misZ: 5.2206 (above the threshold of 3.09). Trascript score misZ: 7.6022 (above the threshold of 3.09). GenCC associations: The gene is linked to familial or sporadic hemiplegic migraine, myoclonic-astatic epilepsy, arthrogryposis, Dravet syndrome, malignant migrating partial seizures of infancy, generalized epilepsy with febrile seizures plus, type 2, migraine, familial hemiplegic, 3, developmental and epileptic encephalopathy, 6A, familial hemiplegic migraine, generalized epilepsy with febrile seizures plus, genetic developmental and epileptic encephalopathy, Lennox-Gastaut syndrome.
PP3
MetaRNN computational evidence supports a deleterious effect, 0.954
PP5
Variant 2-166038098-G-A is Pathogenic according to our data. Variant chr2-166038098-G-A is described in ClinVar as Pathogenic/Likely_pathogenic. ClinVar VariationId is 12883.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
SCN1ANM_001165963.4 linkc.2624C>T p.Thr875Met missense_variant Exon 18 of 29 ENST00000674923.1 NP_001159435.1

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
SCN1AENST00000674923.1 linkc.2624C>T p.Thr875Met missense_variant Exon 18 of 29 NM_001165963.4 ENSP00000501589.1
SCN1AENST00000303395.9 linkc.2624C>T p.Thr875Met missense_variant Exon 17 of 28 5 ENSP00000303540.4
SCN1AENST00000375405.7 linkc.2591C>T p.Thr864Met missense_variant Exon 15 of 26 5 ENSP00000364554.3
SCN1AENST00000409050.2 linkc.2540C>T p.Thr847Met missense_variant Exon 17 of 28 5 ENSP00000386312.1

Frequencies

GnomAD3 genomes
Cov.:
32
GnomAD4 exome
AF:
0.00000137
AC:
2
AN:
1460730
Hom.:
0
Cov.:
32
AF XY:
0.00000138
AC XY:
1
AN XY:
726462
show subpopulations
African (AFR)
AF:
0.00
AC:
0
AN:
33394
American (AMR)
AF:
0.00
AC:
0
AN:
44626
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
26124
East Asian (EAS)
AF:
0.00
AC:
0
AN:
39662
South Asian (SAS)
AF:
0.00
AC:
0
AN:
86190
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
53414
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
5768
European-Non Finnish (NFE)
AF:
0.00000180
AC:
2
AN:
1111212
Other (OTH)
AF:
0.00
AC:
0
AN:
60340
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.450
Heterozygous variant carriers
0
0
1
1
2
2
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Variant carriers
0
2
4
6
8
10
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
Cov.:
32
Alfa
AF:
0.00
Hom.:
0
EpiCase
AF:
0.0000545
EpiControl
AF:
0.00

ClinVar

Significance: Pathogenic/Likely pathogenic
Submissions summary: Pathogenic:9Other:1
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

Generalized epilepsy with febrile seizures plus, type 2 Pathogenic:2
Apr 01, 2000
OMIM
Significance:Pathogenic
Review Status:no assertion criteria provided
Collection Method:literature only

- -

Mar 22, 2022
3billion
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

The variant has been observed in at least two similarly affected unrelated individuals (PMID: 10742094, 23195492) and has been reported to co-segregate with the disease in at least 7 similarly affected relatives/individuals in at least two unrelated families (PMID: 10742094, 23195492). Functional studies provide strong evidence of the variant having a damaging effect on the gene or gene product (PMID: 12086636, 11567038, 14702334). In silico tool predictions suggest damaging effect of the variant on gene or gene product (REVEL: 0.983>=0.6, 3CNET: 0.989>=0.75). It is not observed in the gnomAD v2.1.1 dataset. Different pathogenic/likely pathogenic amino acid change has been reported with supporting evidence at the same codon (PMID:18930999). Therefore, this variant is classified as pathogenic according to the recommendation of ACMG/AMP guideline. -

not provided Pathogenic:2
May 16, 2024
GeneDx
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Reported previously in association with GEFS+ and severe myoclonic epilepsy of infancy, borderline phenotype (PMID: 23195492, 10742094, 18804930); Published functional studies demonstrate a damaging effect and show that this variant impairs the channel function by enhancing channel inactivation (PMID: 11422459, 11567038, 12086636); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Not observed at significant frequency in large population cohorts (gnomAD); This substitution is predicted to be within the intracellular loop between with S4 and S5 transmembrane segments of the second homologous domain; This variant is associated with the following publications: (PMID: 14672992, 11422459, 14702334, 11567038, 12086636, 23195492, 16550559, 18804930, 20831750, 31440721, 35074891, 28717674, 10742094, 36672771) -

Jul 01, 2021
CeGaT Center for Human Genetics Tuebingen
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Inborn genetic diseases Pathogenic:1
Oct 06, 2016
Ambry Genetics
Significance:Likely pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

The p.T875M variant (also known as c.2624C>T), located in coding exon 15 of the SCN1A gene, results from a C to T substitution at nucleotide position 2624. The threonine at codon 875 is replaced by methionine, an amino acid with similar properties. This variant was originally identified in eleven affected members of a family with generalized epilepsy with febrile seizures plus type 2 (Escayg A et al. Nat. Genet., 2000 Apr;24:343-5). This alteration was also reported in a patient with severe myoclonic epilepsy borderline (Wang JW et al. Epilepsy Res., 2012 Dec;102:195-200). This variant was previously reported in the SNPDatabase as rs121918623, but not in NHLBI Exome Sequencing Project (ESP) and 1000 Genomes Project. In the ESP, this variant was not observed in 6502 samples (13004 alleles) with coverage at this position. This amino acid position is highly conserved in available vertebrate species. Based on the majority of available evidence to date, this variant is likely to be pathogenic. -

Developmental and epileptic encephalopathy Pathogenic:1
Dec 09, 2023
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This sequence change replaces threonine, which is neutral and polar, with methionine, which is neutral and non-polar, at codon 875 of the SCN1A protein (p.Thr875Met). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individual(s) with generalized epilepsy with febrile seizures plus in a family (GEFS+) and borderline severe myoclonic epilepsy in infancy (SMEB) (PMID: 10742094, 23195492; Invitae). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 12883). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt SCN1A protein function with a positive predictive value of 95%. Experimental studies have shown that this missense change affects SCN1A function (PMID: 11567038, 12086636, 14702334). This variant disrupts the p.Thr875 amino acid residue in SCN1A. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 18930999, 20522430, 28192756). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. -

SCN1A-related disorder Pathogenic:1
Jun 26, 2024
PreventionGenetics, part of Exact Sciences
Significance:Pathogenic
Review Status:no assertion criteria provided
Collection Method:clinical testing

The SCN1A c.2624C>T variant is predicted to result in the amino acid substitution p.Thr875Met. This variant was reported in multiple individuals with generalized epilepsy with febrile seizures plus (see for example, Escayg et al. 2000. PubMed ID: 10742094). It has been reported to be de novo and segregate with disease (Table S1, Halfmeyer et al. 2022. PubMed ID: 36672771; Escayg et al. 2000. PubMed ID: 10742094). Functional studies indicate this variant affects protein function (Spampanato et al. 2004. PubMed ID: 14702334). This variant has not been reported in a large population database, indicating this variant is rare. This variant is interpreted as pathogenic. -

Seizure Pathogenic:1
May 14, 2024
Génétique des Maladies du Développement, Hospices Civils de Lyon
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Severe myoclonic epilepsy in infancy Pathogenic:1
Jun 20, 2017
Institute of Human Genetics, University of Leipzig Medical Center
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant was identified as de novo (maternity and paternity confirmed). -

Generalized epilepsy with febrile seizures plus, type 1 Other:1
-
UniProtKB/Swiss-Prot
Significance:not provided
Review Status:no classification provided
Collection Method:literature only

- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
0.92
BayesDel_addAF
Pathogenic
0.56
D
BayesDel_noAF
Pathogenic
0.57
CADD
Pathogenic
27
DANN
Pathogenic
1.0
DEOGEN2
Pathogenic
0.98
.;.;.;D;.;.;D;.;.;.
Eigen
Pathogenic
1.0
Eigen_PC
Pathogenic
0.93
FATHMM_MKL
Uncertain
0.97
D
LIST_S2
Pathogenic
0.97
D;D;D;D;.;D;.;.;D;D
M_CAP
Pathogenic
0.95
D
MetaRNN
Pathogenic
0.95
D;D;D;D;D;D;D;D;D;D
MetaSVM
Pathogenic
1.1
D
MutationAssessor
Pathogenic
3.6
.;.;.;H;.;.;H;.;.;.
PhyloP100
10
PrimateAI
Pathogenic
0.90
D
PROVEAN
Pathogenic
-5.7
.;.;.;D;.;.;D;.;D;D
REVEL
Pathogenic
0.98
Sift
Pathogenic
0.0
.;.;.;D;.;.;D;.;D;D
Sift4G
Pathogenic
0.0
.;.;.;D;.;.;D;.;D;D
Polyphen
1.0
.;.;.;D;D;.;D;D;D;.
Vest4
0.87, 0.81, 0.81, 0.82
MutPred
0.78
.;Gain of MoRF binding (P = 0.13);.;Gain of MoRF binding (P = 0.13);.;.;Gain of MoRF binding (P = 0.13);.;.;.;
MVP
1.0
MPC
2.7
ClinPred
1.0
D
GERP RS
4.9
Varity_R
0.84
gMVP
0.98
Mutation Taster
=0/100
disease causing (ClinVar)

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs121918623; hg19: chr2-166894608; COSMIC: COSV57669847; COSMIC: COSV57669847; API